文献速递银屑病与炎症性皮肤病

阿达木单抗生物类似药治疗银屑病的药物生存与安全性:多国队列研究

Drug survival and safety of biosimilars for treating psoriasis compared with originator adalimumab: a multinational cohort study.
PubMed 文献 · Br J Dermatol · 2025-01-01

本研究利用法国、英国和西班牙三个大型数据库,比较阿达木单抗生物类似药与修美乐(Humira)在银屑病患者中的药物生存率和安全性。结果显示,新使用生物类似药者与修美乐新使用者的停药率和严重不良事件风险无差异,但从修美乐转换为生物类似药者的停药率更高。

要点

  • 生物类似药新使用者与修美乐新使用者的全因停药风险无显著差异(HR 0.99)。
  • 从修美乐转换为生物类似药的患者停药风险显著高于继续使用修美乐者(HR 1.35)。
  • 两组严重不良事件风险相似,生物类似药可作为新患者的可行选择。

核心结论

  • 阿达木单抗生物类似药可作为新患者的可行替代方案,疗效与安全性相当。
  • 从修美乐转换为生物类似药的患者停药可能性更高,可能需要更密切监测和支持。

研究设计与样本

  • 采用流行新用户队列研究设计,数据来自法国国家健康数据系统、英国皮肤病医师协会生物制剂和免疫调节剂注册库及西班牙银屑病系统治疗注册库。
  • 新使用生物类似药患者与修美乐新使用者按既往阿达木单抗暴露时间1:1匹配,共匹配7387名生物类似药新用户和3654名转换者。
  • 转换者(从修美乐转为生物类似药)与继续使用修美乐者进行比较,同样按既往暴露时间1:1匹配。
  • 使用Cox比例风险模型计算风险比,并采用随机效应模型对三个数据库结果进行荟萃分析。

主要发现

  • 生物类似药新用户与修美乐新用户的全因停药风险无差异(HR 0.99,95%CI 0.94-1.04)。
  • 从修美乐转换为生物类似药者的停药风险高于继续使用修美乐者(HR 1.35,95%CI 1.19-1.52)。
  • 因无效或不良事件导致的停药结果与全因停药相似。
  • 生物类似药新用户与修美乐新用户的严重不良事件风险相似(IRR 0.91,95%CI 0.80-1.05)。
  • 转换者与持续使用修美乐者的严重不良事件风险相似(IRR 0.92,95%CI 0.83-1.01)。

关键数值与推荐

  • 生物类似药新用户全因停药HR 0.99(95%CI 0.94-1.04),与修美乐新用户无差异。
  • 转换者全因停药HR 1.35(95%CI 1.19-1.52),高于持续使用修美乐者。
  • 生物类似药新用户严重不良事件IRR 0.91(95%CI 0.80-1.05)。
  • 转换者严重不良事件IRR 0.92(95%CI 0.83-1.01)。

临床怎么用

  • 对于未使用过阿达木单抗的银屑病患者,可考虑使用生物类似药作为修美乐的替代方案。
  • 对于从修美乐转换为生物类似药的患者,应加强监测和支持,以降低停药风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The lack of evidence from routine clinical settings has limited the widespread adoption of adalimumab biosimilars for the treatment of psoriasis. OBJECTIVES: To compare the drug survival and safety of adalimumab biosimilars with Humira® in psoriasis. METHODS: We conducted a prevalent new-user cohort study using data from the French National Health Data System (SNDS), the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) and the Spanish Registry of Systemic Therapy in Psoriasis (BIOBADADERM). Adalimumab-naïve patients initiating adalimumab biosimilars (new users) were compared with Humira new users. Patients switching from Humira to biosimilars (switchers) were compared with those who continued Humira treatment. Patients were matched 1 : 1 based on previous adalimumab exposure time to create equal-sized cohorts of biosimilar and Humira users. Co-primary outcomes included drug discontinuation and serious adverse events (SAEs). Hazard ratios (HRs) were calculated using Cox proportional hazard models. Meta-analyses using random-effect models were performed to combine results from the three databases. RESULTS: In total, 7387 biosimilar new users and 3654 switchers were matched and compared with Humira users. No differences in all-cause discontinuation were found between biosimilar and Humira new users [HR 0.99, 95% confidence interval (CI) 0.94-1.04]. Switching from Humira to biosimilars was associated with a higher discontinuation rate than remaining on Humira (HR 1.35, 95% CI 1.19-1.52). Similar results were observed for discontinuation due to ineffectiveness or adverse events. Risks of SAEs were similar between biosimilar new users and Humira new users [incidence rate ratio (IRR) 0.91, 95% CI 0.80-1.05] or between switchers and continuous Humira users (IRR 0.92, 95% CI 0.83-1.01). CONCLUSIONS: Adalimumab biosimilars can be considered viable alternatives to Humira for new patients, with comparable effectiveness and safety. However, owing to the higher likelihood of discontinuation, patients who switch from Humira to biosimilars may require closer monitoring and support. Psoriasis is a long-term inflammatory skin disease that affects over 60 million people globally. Adalimumab is a drug often used to treat moderate to severe psoriasis. The original adalimumab brand (called Humira®) is expensive and adds pressure to health care systems. ‘Biosimilars’ are drugs that are similar to Humira. They became available in Europe in 2018. These drugs could help cut costs and make treatment more accessible. This study looked at how long people stayed on treatment. It also looked at the safety of adalimumab biosimilars in people with psoriasis. Information from large health databases in France, the UK and Spain was used to compare two groups. The first group included people who started on either biosimilars or Humira for the first time. The second included people who switched from Humira to biosimilars compared with those who kept taking Humira. There was no difference in how long new users of biosimilars stayed on treatment compared with new users of Humira. Patients who switched from Humira to biosimilars were more likely to stop treatment than those who kept using Humira. The risk of serious side effects was similar for both biosimilar and Humira users. Our findings suggest that biosimilars are as safe and effective as Humira. Patients who switch to biosimilars from Humira are more likely to stop treatment. More research is needed to understand the effects of switching.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Phan DB, Jourdain H, Descalzo-Gallego MA, et al. Drug survival and safety of biosimilars for treating psoriasis compared with originator adalimumab: a multinational cohort study. Br J Dermatol. 2025. PMID: 39565180. doi:10.1093/bjd/ljae454

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。